Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Dr. Martens Plc ( (GB:DOCS) ) is now available.
Dr. Martens reported a modest decline in third-quarter group revenue as it pushed ahead with a “consumer-first” turnaround that prioritises full-price sales over discounting, particularly in ecommerce. For the 13 weeks to 28 December 2025, revenue fell 2.7% at constant currency to £253m, with direct-to-consumer sales down 6.5% and wholesale up 9.5%, reflecting a deliberate pullback from clearance activity and a tougher consumer backdrop, especially in EMEA where DTC revenue slumped 12% while wholesale grew 13%. The Americas delivered 2% revenue growth, driven by stronger retail and a more disciplined wholesale mix, and APAC saw a small overall decline as reduced promotions hit DTC but boosted full-price performance, with South Korea continuing to grow strongly. Management said it is on track to deliver all four strategic objectives for FY26, including reducing reliance on discounted wholesale in the US, expanding newer product families, opening new markets via capital-light partnerships—such as an expanded Latin American distribution deal—and simplifying its operating model to be closer to local consumers. Despite expecting broadly flat constant-currency revenue for FY26 as it prioritises profitability and revenue quality, Dr. Martens reiterated guidance for significant year-on-year growth in profit before tax, though it warned that foreign exchange volatility now implies a larger revenue headwind and a broadly neutral effect on adjusted PBT.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £100.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Spark’s Take on GB:DOCS Stock
According to Spark, TipRanks’ AI Analyst, GB:DOCS is a Neutral.
Dr. Martens Plc’s overall stock score reflects a mix of financial challenges and strategic progress. The most significant factor is the company’s financial performance, which is hindered by declining revenue and profitability. Technical analysis indicates bearish momentum, while valuation suggests the stock is overvalued. Positive corporate events and earnings call insights provide some optimism, but challenges remain.
To see Spark’s full report on GB:DOCS stock, click here.
More about Dr. Martens Plc
Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England, best known for its original 1460 boot and other “Docs” silhouettes that evolved from workwear into global subcultural fashion staples. Operating in more than 60 countries with a workforce of around 3,700, the company sells through direct-to-consumer retail and ecommerce channels as well as wholesale, offering classic boots, shoes and sandals alongside newer franchises such as Zebzag, Buzz and Lowell, plus kids’ ranges and accessories, all positioned around craftsmanship, heritage and timeless style.
Average Trading Volume: 972,752
Technical Sentiment Signal: Sell
Current Market Cap: £731.2M
For an in-depth examination of DOCS stock, go to TipRanks’ Overview page.